3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Nasopharyngeal Carcinoma
7
Esophageal Squamous Cell Carcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Advanced Breast Cancer
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Mouth Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
toripalimab
×
90 days
×
Clear all
NCT07423078
2026-04-13
WOLF
University of Pittsburgh
Phase 2
Recruiting
87 enrolled